-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cinda Biopharmaceuticals announced the signing of a non-exclusive, target-specific license agreement with Synaffix BV
According to the terms of the agreement, Synaffix will provide the necessary proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and a certain linker-toxin under its toxSYN™ platform, enabling Innovent to quickly develop its own antibody based on its own antibody and have the best in class Potential ADC candidate molecule
After the agreement is signed, Cinda Biotech has the right to use the aforementioned ADC technology on the candidate molecule
According to the agreement, Synaffix will receive the first payment for cooperation and will be eligible to receive milestone payments related to specific R&D progress and sales, as well as future royalties for the ADC product based on commercial net sales
Note: The original text has been deleted